Synthetic introduction of aglyconic substitutions into carbohydrate ligands is an approach toward identifying potent inhibitors of medically relevant lectins. We tested a panel of 27 galactoside/lactoside derivatives harboring varying aglycone moieties together with some O-3/O-3′ functionality toward a biohazardous plant toxin and four human adhesion/growth-regulatory galectins. Differential sensitivity profiles of lectin binding with cases showing activity increase relative to galactose/lactose were revealed by systematic assessments using a solid-phase assay. Quantitative differences between the homologous human proteins could even be detected. Binding of substituted lactosides to galectins-1 and -3 was shown to be enthalpically driven. To determine the potential of substituted glycosides to protect cells from harmful lectin association, binding assays with human tumor cells were performed. Invariably, compounds were identified with increased potency relative to the unsubstituted parent sugars. However, aglyconic substitutions were shown to be able to convey cytotoxicity. This report directs further attention to examining additional 2′- and 3′-substitutions of the galactose core and the potential of ligand presentation in glycoclusters to enhance avidity and selectivity, continuing to use the herein applied strategic combination of a convenient biochemical test system with bioassays.
在
碳水化合物配体中合成引入
琼脂取代物,是鉴定医学相关凝集素强效
抑制剂的一种方法。我们测试了 27 种半
乳糖苷/
乳糖苷衍
生物,这些衍
生物含有不同的
琼脂酮分子和一些 O-3/O-3′ 功能,可与一种具有
生物危害性的植物毒素和四种人类粘附/生长调节半凝集素结合。通过使用固相分析法进行系统评估,发现了凝集素结合的不同敏感性特征,以及相对于半
乳糖/
乳糖活性增加的情况。甚至还能检测到同源人类蛋白质之间的数量差异。研究表明,取代的
乳糖与半
乳糖-1 和半
乳糖-3 的结合是由热驱动的。为了确定取代的苷类化合物保护细胞免受有害凝集素结合的潜力,进行了与人类肿瘤细胞的结合试验。与未取代的母糖相比,经鉴定的化合物总是具有更强的效力。不过,
琼脂取代物被证明能够传递细胞毒性。本报告引导人们进一步关注研究半
乳糖核心的其他 2′-和 3′-取代,以及
配体在糖团中的呈递潜力,以提高亲和性和选择性,并继续使用本报告中应用的便捷生化测试系统与
生物测定的战略结合。